title: Indications and limitations of vismodegib for basal cell carcinoma--reply.
authors.affiliation: Department of Ophthalmology and Vision Sciences, University of Toronto, Mount Sinai Hospital, Toronto, Ontario, Canada.
authors.forename: Harmeet S
authors.initials: HS
authors.lastname: Gill
authors.affiliation: Division of Oculofacial Plastic and Orbital Surgery, California Pacific Medical Center, Oakland.
authors.forename: Eve E
authors.initials: EE
authors.lastname: Moscato
authors.affiliation: Division of Ophthalmic Plastic, Reconstructive, and Orbital Surgery, California Pacific Medical Center, Oakland.
authors.forename: Rona Z
authors.initials: RZ
authors.lastname: Silkiss
mesh_terms: D000813:Anilides / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D005142:Eyelid Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D009918:Orbital Neoplasms / Q000188:drug therapy*; D011725:Pyridines / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000813:Anilides; D000970:Antineoplastic Agents; D011725:Pyridines